百利天恒递表港交所 高盛、摩根大通、中信证券为联席保荐人

Core Insights - Bailitianheng has submitted a listing application to the Hong Kong Stock Exchange, with Goldman Sachs, JPMorgan, and CITIC Securities as joint sponsors [1] Company Overview - Bailitianheng is a comprehensive biopharmaceutical company focused on tumor macromolecule therapy (ADC/GNC/ARC) [1] - The company established SystImmune in the United States and successfully developed the world's first EGFR×HER3 bispecific ADC drug, iza-bren (BL-B01D1), which has entered Phase III clinical development [1] Strategic Partnerships - In 2024, Bailitianheng reached a global strategic licensing and collaboration deal with BMS for iza-bren worth up to $8.4 billion, including an upfront payment of $800 million [1] Research and Development Pipeline - The company has established an innovative ADC drug research and development platform with 9 ADC candidates currently in clinical stages [1] - Bailitianheng has built a multispecific T-cell connector platform with 4 GNC innovative drug pipelines [1] - The company has also developed an innovative ARC drug research platform, with the ARC drug BL-ARC001 submitted for IND, which has the potential to become a global first [1]